Company / Working Capital
Enliven Therapeutics, Inc. Working Capital History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$302.2M
FY2024
5-year range
$68.0M / $302.2M
FY2020-FY2024
Trend
+25.8%
vs FY2023
Sector context
#139 of 213
Health Care
What the data says
At $302M, Enliven Therapeutics, Inc.'s working capital ranks #139 of 213 in the Health Care sector. Improved from $68M to $302M over the past 2 years.
Based on SEC 10-K filings.
$302M in FY2024 with a 5-year CAGR of +62.8%.
Improved from $68M to $302M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +52.3%
- 5-Year CAGR
- +62.8%
- 10-Year CAGR
- -
Sector benchmark
#139 of 213 in Health CareTop 65% of 213This company $302.2M Sector average $934.6M
▼
-67.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +62.8%, indicating consistent growth.
- In FY2024, working capital increased 25.8% year-over-year.
- Ranks #139 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $302.2M | +25.8% |
| FY2023 | $240.3M | +253.1% |
| FY2022 | $68.0M | -20.4% |
| FY2021 | $85.5M | +1.6% |
| FY2020 | $84.2M | +218.5% |
| FY2019 | $26.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026